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operative anaesthetic requirements and post-operative nausea and vomiting in dogs 
undergoing routine ovariohysterectomy. 
 
Abstract:  (Your abstract must use Normal style and must fit into the box. Do not enter author details) 
Objectives: To establish if pre-operative maropitant significantly reduced intra-operative 
isoflurane requirement and reduced clinical signs associated with post-operative nausea and 
vomiting (PONV) in dogs.  
 
Methods: 24 client-owned dogs presenting for ovariohysterectomy were enrolled into this 
prospective, double-blinded, randomised clinical trial. Eligible dogs were 0.4-8 years old, ASA 
grade 1-2 and not pregnant/ displaying signs of pseudocyesis or oestrus. Pre-medication 
consisted of acepromazine (0.03mg/kg) combined with methadone (0.3mg/kg) intra-muscularly 
45 minutes before anaesthetic induction with intravenous propofol, dosed to effect. Meloxicam 
(0.2mg/kg) was given intravenously following cephalic vein catheterization. Additionally, at 
premedication, dogs were randomly assigned to receive saline (group S) (0.1ml/kg 
subcutaneously, n=12) or maropitant (group M) (1mg/kg subcutaneously, n=12). Methadone 
(0.1mg/kg intravenously) was repeated four hours later. Anaesthesia was maintained with 
isoflurane in oxygen, dosed to effect (same blinded observer). Monitored patient parameters 
included heart rate, non-invasive blood pressure, pulse oximetry, temperature, capnography and 
end-tidal isoflurane concentration (ETIso). Post-operatively, dogs were assessed hourly using 
the short form of the Glasgow Composite Pain Score (GCPS) and examined for clinical signs 
attributable to PONV [scored from 0 (none) to 3 (severe)]. A t-test was used to asses mean 
ETIso. Remaining variables were analyzed using Mann-Whitney U tests. Significance was set at 
P<0.05.  
 
Results: Mean ±SD ETIso was lower in group M (1.19 ± 0.26%) than group S (1.44 ± 0.23%) 
(P=0.022). Group M had lower median [range] ETIso first incision (1.02% [0.77-1.8%]) and at 1st 
ovarian pedicle ligation (1.13% [0.50-1.84%]) than group S (1.45% [0.81-1.9%] and 1.45% [0.69-
3.2%]; P=0.03 and P=0.02 respectively). No other cardiorespiratory variables or post-operative 
GCPS differed significantly between groups. Overall, 50% of dogs displayed signs attributable to 
PONV, with no significant difference in PONV scores between groups (P=0.198).  
 
Conclusion: Maropitant reduced intra-operative isoflurane requirements, although not 
consistently and did not significantly affect the incidence of PONV. 
 
 
